Articles

Each year, approximately 250,000 cases of breast cancer are diagnosed in the United States. Read More ›

A recent review of the various approaches to developing new therapeutic drugs to treat KRAS-harboring tumors also discusses emerging drugs. Read More ›

Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors. Read More ›

A retrospective cohort study demonstrates patients with inoperable non–small-cell lung cancer receiving aspirin have improved overall survival compared with patients not receiving aspirin. Read More ›

A recent review of case reports of patients with non–small-cell lung cancer receiving immune checkpoint therapy finds neurologic adverse events are a rare but concerning side effect. Read More ›

In 2021, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Read More ›

Results of the primary analysis of the phase 3b OPINION study supported the use of olaparib maintenance therapy in patients with nongermline BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer. Read More ›

The final overall survival analysis of the phase 2 LIGHT study indicates that olaparib therapy in patients with platinum-sensitive relapsed ovarian cancer provides overall survival benefit across patient cohorts, regardless of BRCA mutation and homologous recombination deficiency status, with a safety profile consistent with that previously described. Read More ›